ReviewWorld journal of gastroenterology2016
Emerging role of Hippo pathway in gastric and other gastrointestinal cancers.
Review in World journal of gastroenterology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 102 citations in OpenAlex.
- G protein-coupled receptors: pivotal hubs in gastric cancer malignancy-from multidimensional crosstalk to precision therapeutics.Journal of translational medicine · 2025Review
- USP12 facilitates gastric cancer progression via stabilizing YAP.Cell death discovery · 2024Article
- Abnormal activation of RFC3, A YAP1/TEAD downstream target, promotes gastric cancer progression.International journal of clinical oncology · 2024Article
- Helicobacter pylori-induced aberrant demethylation and expression of GNB4 promotes gastric carcinogenesis via the Hippo-YAP1 pathway.BMC medicine · 2023Article
- Signaling pathways of oxidative stress response: the potential therapeutic targets in gastric cancer.Frontiers in immunology · 2023Review
- Review
- RBCK1 is an endogenous inhibitor for triple negative breast cancer via hippo/YAP axis.Cell communication and signaling : CCS · 2022Article
- DUB1 suppresses Hippo signaling by modulating TAZ protein expression in gastric cancer.Journal of experimental & clinical cancer research : CR · 2022Article
- HIPPO signaling-related signature for predicting prognosis and therapeutic response in gastric cancer.Frontiers in pharmacology · 2022Article
- Hippo pathway: Regulation, deregulation and potential therapeutic targets in cancer.Cancer letters · 2021Review
- Antitumor Effects of Paeoniflorin on Hippo Signaling Pathway in Gastric Cancer Cells.Journal of oncology · 2021Article
- [Emerging roles of Hippo signaling pathway in gastrointestinal cancers and its molecular mechanisms].Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences · 2020Review
- A Middle-Out Modeling Strategy to Extend a Colon Cancer Logical Model Improves Drug Synergy Predictions in Epithelial-Derived Cancer Cell Lines.Frontiers in molecular biosciences · 2020Article
- Flaming the fight against cancer cells: the role of microRNA-93.Cancer cell international · 2020Review
- Review
- Analysis of the role of the Hippo pathway in cancer.Journal of translational medicine · 2019Review
- The Hippo Pathway and Viral Infections.Frontiers in microbiology · 2019Review
- Nitidine Chloride inhibits cell proliferation and invasion via downregulation of YAP expression in prostate cancer cells.American journal of translational research · 2019Article
- Targeting the miR-630/YAP1/ERK feedback loop in epidermal growth factor receptor-mutated lung adenocarcinomas.Journal of thoracic disease · 2018Article
- SRGAP1, a crucial target of miR-340 and miR-124, functions as a potential oncogene in gastric tumorigenesis.Oncogene · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
More evidence has underscored the importance of Hippo signaling pathway in gastrointestinal tissue homeostasis, whereas its deregulation induces tumorigenesis. Yes-associated protein 1 (YAP1) and its close paralog TAZ, transcriptional co-activator with a PDZ-binding motif, function as key effectors negatively controlled by the Hippo pathway. YAP1/TAZ exerts oncogenic activities by transcriptional regulation via physical interaction with TEAD transcription factors. In various cancers, Hippo pathway cross-talks with pro- or anti-tumorigenic pathways such as GPCR, Wnt/β-catenin, Notch and TGF-β signaling and is deregulated by multiple factors including cell density/junction and microRNAs. As YAP1 expression is significantly associated with poor prognosis of gastric and other gastrointestinal cancers, detailed delineation of Hippo regulation in tumorigenesis provides novel insight for therapeutic intervention. In current review, we summarized the recent research progresses on the deregulation of Hippo pathway in the gastrointestinal tract including stomach and discuss the molecular consequences leading to tumorigenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.